Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
psilocybin + D-serine
- Development stage
- Unknown
- Lead developer
- Hadassah Medical Organization
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
psilocybin + D-serine is a combination drug product being developed by the Hadassah Medical Organization for the treatment of psychiatric conditions, including depression and anxiety. The formulation combines psilocybin, a naturally occurring psychedelic prodrug that is converted into psilocin, a potent agonist of the 5-HT2A serotonin receptor, with D-serine, an endogenous amino acid that serves as a mandatory co-agonist at the glycine binding site of the N-methyl-D-aspartate (NMDA) receptor. This combination aims to leverage the rapid-acting antidepressant effects of psilocybin while utilizing D-serine to potentially modulate the psychedelic experience and enhance neuroplasticity through glutamatergic pathways. It is currently being evaluated in Phase 1 clinical trials to assess safety, tolerability, and psychological effects in healthy volunteers as a precursor to studies in patient populations.
- Other names
- Psilocybin and D-Serine formulation
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on psilocybin + D-serine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on psilocybin + D-serine.